CD52 and autoimmune thrombocytopenia: Also supporting an inhibitory role for CD52 is the observation that 20% and 3% of MS patients treated with lymphocyte-depleting alemtuzumab develop thyroid autoimmunity and autoimmune thrombocytopenia respectively within months or years after start of treatment.